Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 4;19(1):5.
doi: 10.1186/s12957-020-02111-3.

Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy

Affiliations

Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy

Mahmoud Mustafa et al. World J Surg Oncol. .

Abstract

Purpose: To define the efficacy of standard androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer (PCa).

Materials and methods: Fifty patients with mean age of 70.48 ± 9.95 years old (range 52-87) who had metastatic PCa and received ADT between 2014 and 2019 were retrospectively evaluated. Median values of pre-therapeutic PSA and Gleason scores were 50 ng/ml (range 8-1201) and 8 (range 6-9), respectively. All patients received luteinizing hormone-releasing hormone (LHRH) analogue and anti-androgen. The patients were evaluated in terms of age, pre-therapeutic PSA serum levels, Gleason scores, presence of metastasis, number and percentage of cores involved, nadir PSA, time to nadir PSA, duration of ADT, and PSA at last follow-up. Multivariate analysis was used to define the factors which have impact on ADT response. The mean follow-up period was 13.87 ± 7.78 months, (range 2-32).

Results: All patients showed reduction in serum PSA level after initiation of ADT, and the median value of nadir PSA was 1.12 ng/ml (range 0.02-50). The mean value of time to nadir PSA was 3.85 ± 1.57 months (range 2-7). The median value of PSA at last follow-up was 2 ng/ml (range 0.02-50.21). Multi-variant analysis showed that nadir PSA have a significant correlation with pre-therapeutic PSA, PSA at last follow-up, age, and Gleason scores (p < .05).

Conclusion: Standard ADT is a feasible option in the treatment of metastatic PCa. Gleason scores, age, pre-therapeutic PSA, and PSA at last follow-up have significant impact on outcomes of ADT. Further studies of high number of patients with long-term follow-up including other chemo-hormonal therapy and androgen receptor blockers should be carried out to confirm and improve efficacy of ADT.

Keywords: Hormonal therapy; Prostate; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest declared between the authors.

References

    1. Chen FZ, Zhao XK. Prostate cancer: current treatment and prevention strategies. Iran Red Crescent Med J. 2013;15(4):279–284. doi: 10.5812/ircmj.6499. - DOI - PMC - PubMed
    1. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319. doi: 10.1056/NEJMoa0810696. - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Abdelsalam RA, Khalifeh I, Box A, Kalantarian M, Ghosh S, Abou-Ouf H, et al. Molecular characterization of prostate cancer in middle eastern population highlights differences with western populations with prognostic implication. J Cancer Res Clin Oncol. 2020;3. - PMC - PubMed
    1. Tosoian JJ, Almutairi F, Morais CL, Glavaris S, Hicks J, Sundi D, et al. Prevalence and prognostic significance of PTEN loss in African-American and European-American men undergoing radical prostatectomy. Eur Urol. 2017;71(5):697–700. doi: 10.1016/j.eururo.2016.07.026. - DOI - PMC - PubMed

Substances